Table 1 Double-blind, randomized, placebo-controlled crossover studies of treatment of children with fragile X syndrome a
Clinical trial registration number | Type | Compound | Population | Target | Status | Promoter | Results (reported or pending) |
|---|---|---|---|---|---|---|---|
Phase II multicentre | NNZ-2566 | Adolescent and adult males | NMDA antagonists | Recruiting | Neuren Pharmaceuticals (USA) | Pending | |
Phase II single centre | Ganaxolone | Adolescents and children | GABA-A agonist | Recruiting | Marinus Pharmaceuticals (USA) | Pending | |
Phase II single centre | Metadoxine (MG01CI) | Adults and adolescents | Ion pair of pyridoxine (vitamin 6) | Not yet recruiting | Alcobra Pharma (USA) | Pending | |
Phase II single centre | Sertraline | Children | Selective serotonin reuptake inhibitors | Recruiting | University of California, Davis (USA) | Pending | |
Phase II and III Multicentre | Acamprosate | Adolescents and children | NMDA receptor modulators | Recruiting | Children’s Hospital Medical Center (Cincinnati, OH, USA) | Pending | |
Phase II multicentre | Mavoglurant (AFQ056) | Adolescents and adults | mGlur5 antagonist | Terminated | Novartis (Basel, Switzerland) | [62] | |
Phase II multicentre | Arbaclofen (STX209) | Adolescents and adults | GABA-B agonist | Terminated | Seaside Therapeutics (USA) | [63] | |
[64] | |||||||
Phase II single centre | Minocycline | Adolescents and children | Antibiotic | Completed | University of California, Davis (USA) | [65] | |
Phase II multicentre | Basimglurant (RO4917523) | Adults | mGlur5 antagonist | Completed | Hoffmann-La Roche | Pending | |
Phase IV single centre | Riluzole | Adults | Inhibitor of glutamate release | Completed | Indiana University (USA) | [66] | |
Phase II single centre | Oxytocin | Adolescents and adults | Social brain neuropeptides | Completed | Stanford University (USA) | [67] | |
Open label | Donepezil | Adolescents and children | Cholinergic drug | Completed | Stanford University (USA) | [68] |